QART Medical is excited to share a recent Jerusalem Post article which featured QART Medical’s advanced technology and improvement of IVF success rates. The piece highlights Professor Shaked’s groundbreaking work in advancing IVF technology, specifically through QART Medical’s pioneering use of quantitative phase microscopy to analyze sperm cells in a clinical setting. Said Professor Shaked, “The continued media coverage and recognition of QART’s work underscores the transformative potential of our technology, and we look forward to further revolutionizing the IVF industry. We’re thrilled that sustained media attention is helping to spread the word about our work and the impact it will have on the future of IVF.”
To read the article on the Jerusalem Post website please Click Here.
Professor Natan Shaked, cofounder of QART Medical
QART Medical is an ISO13485 certified MedTech company addressing the global infertility epidemic. To do so, QART has developed the Q300™, a breakthrough solution to male infertility issues that provides a quantitative characterization of sperm cell morphology to facilitate informed clinical decision making when selecting cells for use in in-vitro fertilization (IVF). QART aims to improve current success rates of Intra-Cytoplasmic Sperm Injection (ICSI) by quantitatively characterizing the morphology and composition of individual sperm cells with 3D imaging. The Q300™ is registered with the US FDA, has received Israeli regulatory registration for commercial sales, and bears the CE (Conformité Européenne) Mark.